These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

473 related articles for article (PubMed ID: 30184215)

  • 1. Demethylation and epigenetic modification with 5-azacytidine reduces IDH1 mutant glioma growth in combination with temozolomide.
    Yamashita AS; da Costa Rosa M; Borodovsky A; Festuccia WT; Chan T; Riggins GJ
    Neuro Oncol; 2019 Feb; 21(2):189-200. PubMed ID: 30184215
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutant IDH1 Enhances Temozolomide Sensitivity via Regulation of the ATM/CHK2 Pathway in Glioma.
    Lin L; Cai J; Tan Z; Meng X; Li R; Li Y; Jiang C
    Cancer Res Treat; 2021 Apr; 53(2):367-377. PubMed ID: 33070553
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of a DNA demethylating agent in combination with all-trans retinoic acid for IDH1-mutant gliomas.
    da Costa Rosa M; Yamashita AS; Riggins GJ
    Neuro Oncol; 2022 May; 24(5):711-723. PubMed ID: 34850159
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of D-2HG leads to upregulation of a proinflammatory gene signature in a novel HLA-A2/HLA-DR1 transgenic mouse model of IDH1R132H-expressing glioma.
    Chuntova P; Yamamichi A; Chen T; Narayanaswamy R; Ronseaux S; Hudson C; Tron AE; Hyer ML; Montoya M; Mende AL; Nejo T; Downey KM; Diebold D; Lu M; Nicolay B; Okada H
    J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35606087
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overexpression of isocitrate dehydrogenase mutant proteins renders glioma cells more sensitive to radiation.
    Li S; Chou AP; Chen W; Chen R; Deng Y; Phillips HS; Selfridge J; Zurayk M; Lou JJ; Everson RG; Wu KC; Faull KF; Cloughesy T; Liau LM; Lai A
    Neuro Oncol; 2013 Jan; 15(1):57-68. PubMed ID: 23115158
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epigenetic silencing of XAF1 in high-grade gliomas is associated with IDH1 status and improved clinical outcome.
    Reich TR; Switzeny OJ; Renovanz M; Sommer C; Kaina B; Christmann M; Tomicic MT
    Oncotarget; 2017 Feb; 8(9):15071-15084. PubMed ID: 28122345
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 5-azacytidine reduces methylation, promotes differentiation and induces tumor regression in a patient-derived IDH1 mutant glioma xenograft.
    Borodovsky A; Salmasi V; Turcan S; Fabius AW; Baia GS; Eberhart CG; Weingart JD; Gallia GL; Baylin SB; Chan TA; Riggins GJ
    Oncotarget; 2013 Oct; 4(10):1737-47. PubMed ID: 24077805
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential expression of the TWEAK receptor Fn14 in IDH1 wild-type and mutant gliomas.
    Hersh DS; Peng S; Dancy JG; Galisteo R; Eschbacher JM; Castellani RJ; Heath JE; Legesse T; Kim AJ; Woodworth GF; Tran NL; Winkles JA
    J Neurooncol; 2018 Jun; 138(2):241-250. PubMed ID: 29453678
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IDH1-R132H acts as a tumor suppressor in glioma via epigenetic up-regulation of the DNA damage response.
    Núñez FJ; Mendez FM; Kadiyala P; Alghamri MS; Savelieff MG; Garcia-Fabiani MB; Haase S; Koschmann C; Calinescu AA; Kamran N; Saxena M; Patel R; Carney S; Guo MZ; Edwards M; Ljungman M; Qin T; Sartor MA; Tagett R; Venneti S; Brosnan-Cashman J; Meeker A; Gorbunova V; Zhao L; Kremer DM; Zhang L; Lyssiotis CA; Jones L; Herting CJ; Ross JL; Hambardzumyan D; Hervey-Jumper S; Figueroa ME; Lowenstein PR; Castro MG
    Sci Transl Med; 2019 Feb; 11(479):. PubMed ID: 30760578
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of 2-hydroxyglutarate elicits metabolic reprogramming and mutant IDH1 glioma immunity in mice.
    Kadiyala P; Carney SV; Gauss JC; Garcia-Fabiani MB; Haase S; Alghamri MS; Núñez FJ; Liu Y; Yu M; Taher A; Nunez FM; Li D; Edwards MB; Kleer CG; Appelman H; Sun Y; Zhao L; Moon JJ; Schwendeman A; Lowenstein PR; Castro MG
    J Clin Invest; 2021 Feb; 131(4):. PubMed ID: 33332283
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monoallelic IDH1 R132H Mutation Mediates Glioma Cell Response to Anticancer Therapies via Induction of Senescence.
    Zhan D; Ma D; Wei S; Lal B; Fu Y; Eberhart C; Laterra J; Ying M; Li Y; Meeker A; Lopez-Bertoni H; Xia S
    Mol Cancer Res; 2021 Nov; 19(11):1878-1888. PubMed ID: 34348994
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CRISPR Editing of Mutant IDH1 R132H Induces a CpG Methylation-Low State in Patient-Derived Glioma Models of G-CIMP.
    Moure CJ; Diplas BH; Chen LH; Yang R; Pirozzi CJ; Wang Z; Spasojevic I; Waitkus MS; He Y; Yan H
    Mol Cancer Res; 2019 Oct; 17(10):2042-2050. PubMed ID: 31292202
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IDH1 R132H mutation regulates glioma chemosensitivity through Nrf2 pathway.
    Li K; Ouyang L; He M; Luo M; Cai W; Tu Y; Pi R; Liu A
    Oncotarget; 2017 Apr; 8(17):28865-28879. PubMed ID: 28427200
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isocitrate Dehydrogenase Mutations are Better Prognostic Marker than O6-methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastomas - a Retrospective, Single-centre Molecular Genetics Study of Gliomas.
    Houdova Megova M; Drábek J; Dwight Z; Trojanec R; Koudeláková V; Vrbková J; Kalita O; Mlcochova S; Rabcanova M; Hajdúch M
    Klin Onkol; 2017; 30(5):361-371. PubMed ID: 29031038
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Decreasing GSH and increasing ROS in chemosensitivity gliomas with IDH1 mutation.
    Shi J; Sun B; Shi W; Zuo H; Cui D; Ni L; Chen J
    Tumour Biol; 2015 Feb; 36(2):655-62. PubMed ID: 25283382
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutant IDH1 promotes phagocytic function of microglia/macrophages in gliomas by downregulating ICAM1.
    Ma D; Zhan D; Fu Y; Wei S; Lal B; Wang J; Li Y; Lopez-Bertoni H; Yalcin F; Dzaye O; Eberhart CG; Laterra J; Wilson MA; Ying M; Xia S
    Cancer Lett; 2021 Oct; 517():35-45. PubMed ID: 34098063
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT Inhibitor Decitabine.
    Turcan S; Fabius AW; Borodovsky A; Pedraza A; Brennan C; Huse J; Viale A; Riggins GJ; Chan TA
    Oncotarget; 2013 Oct; 4(10):1729-36. PubMed ID: 24077826
    [TBL] [Abstract][Full Text] [Related]  

  • 18. R132H mutation in IDH1 gene reduces proliferation, cell survival and invasion of human glioma by downregulating Wnt/β-catenin signaling.
    Cui D; Ren J; Shi J; Feng L; Wang K; Zeng T; Jin Y; Gao L
    Int J Biochem Cell Biol; 2016 Apr; 73():72-81. PubMed ID: 26860959
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IDH1 R132H Mutation Enhances Cell Migration by Activating AKT-mTOR Signaling Pathway, but Sensitizes Cells to 5-FU Treatment as NADPH and GSH Are Reduced.
    Zhu H; Zhang Y; Chen J; Qiu J; Huang K; Wu M; Xia C
    PLoS One; 2017; 12(1):e0169038. PubMed ID: 28052098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IDH1 overexpression induced chemotherapy resistance and IDH1 mutation enhanced chemotherapy sensitivity in Glioma cells in vitro and in vivo.
    Wang JB; Dong DF; Wang MD; Gao K
    Asian Pac J Cancer Prev; 2014; 15(1):427-32. PubMed ID: 24528069
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.